mTOR inhibitor

Open Access
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
ERLINDA M. GORDON, NICOLE L. ANGEL, NADEZHDA OMELCHENKO, VICTORIA S. CHUA-ALCALA, ANIA MORADKHANI, DORIS QUON and STEVEN WONG

Anticancer Research May 2023, 43 (5) 1993-2002; DOI: https://doi.org/10.21873/anticanres.16360
You have access
Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
HIROMICHI OSHIRO, YASUNORI TOME, KENTARO MIYAKE, TAKASHI HIGUCHI, NORIHIKO SUGISAWA, FUMINORI KANAYA, KOTARO NISHIDA and ROBERT M. HOFFMAN

Anticancer Research July 2021, 41 (7) 3287-3292; DOI: https://doi.org/10.21873/anticanres.15115
You have access
The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells
SEO YUN KIM, EUN-HUI JEONG, TAE-GUL LEE, HYE-RYOUN KIM and CHEOL HYEON KIM

Anticancer Research June 2021, 41 (6) 2885-2894; DOI: https://doi.org/10.21873/anticanres.15070
You have access
Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma
HISATERU KOMATSU, TAKAAKI MASUDA, TOMOHIRO IGUCHI, SHO NAMBARA, KUNIAKI SATO, QUINGJANG HU, HIDENARI HIRATA, SHUHEI ITO, HIDETOSHI EGUCHI, KEISHI SUGIMACHI, HIDETOSHI EGUCHI, YUICHIRO DOKI, MASAKI MORI and KOSHI MIMORI

Anticancer Research March 2017, 37 (3) 1083-1090;
You have access
Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature
KRISTEN D. STARBUCK, RICHARD D. DRAKE, G. THOMAS BUDD and PETER G. ROSE

Anticancer Research November 2016, 36 (11) 6161-6164;
You have access
Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis
SUNGYUB LEW and RONALD S. CHAMBERLAIN

Anticancer Research April 2016, 36 (4) 1711-1718;
You have access
Risk of Anemia Attributable to Everolimus in Patients with Cancer: A Meta-analysis of Randomized Controlled Trials
RAJI SHAMEEM, MUHAMMAD SAAD HAMID and SHENHONG WU

Anticancer Research April 2015, 35 (4) 2333-2340;
You have access
Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
J. RANDOLPH HECHT, TONY R. REID, CHRISTOPHER R. GARRETT, J. THADDEUS BECK, SHELDON J. DAVIDSON, MARY J. MACKENZIE, ULRIKE BRANDT, SYED RIZVI and SUNIL SHARMA

Anticancer Research March 2015, 35 (3) 1567-1573;
You have access
A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience
CHARLOTTE BENSON, JOANNA VITFELL-RASMUSSEN, MARCO MARUZZO, CYRIL FISHER, NINA TUNARIU, SCOTT MITCHELL, OMAR AL-MUDERIS, KHIN THWAY, JAMES LARKIN and IAN JUDSON

Anticancer Research July 2014, 34 (7) 3663-3668;
You have access
The Mammalian Target of Rapamycin Inhibitors in Breast Cancer: Current Evidence and Future Directions
PAOLA MALAGUTI, SABRINA VARI, FRANCESCO COGNETTI and ALESSANDRA FABI

Anticancer Research January 2013, 33 (1) 21-28;

Main menu

User menu

Search

mTOR inhibitor

Pages